Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use
| Autor: | Jonathan Grotts, Steven Han, Francisco Durazo, David Elashoff, Alexander Farid, Ronald W. Busuttil, Justin Rheem, Gina Choi, Sammy Saab, Sherona Bau, Mohammed El Kabany, Melissa Jimenez, Naadir Jamal |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Chronic Liver Disease and Cirrhosis Renal function 030230 surgery Liver transplantation Gastroenterology Hepatitis 03 medical and health sciences 0302 clinical medicine Hepatitis - C Interquartile range Internal medicine Direct acting agents medicine Immunosuppressant Transplantation Hepatology business.industry Liver Disease Evaluation of treatments and therapeutic interventions Immunosuppression Organ Transplantation Hepatitis C medicine.disease Tacrolimus Surgery stomatognathic diseases Regimen Infectious Diseases Emerging Infectious Diseases 6.1 Pharmaceuticals Original Article 030211 gastroenterology & hepatology Digestive Diseases Infection business After treatment |
| Zdroj: | Journal of clinical and translational hepatology, vol 4, iss 1 Journal of Clinical and Translational Hepatology |
| ISSN: | 2310-8819 2225-0719 |
| DOI: | 10.14218/jcth.2016.00001 |
| Popis: | Background and Aims: All-oral interferon-free antivirals are highly effective in treating recurrent hepatitis C (HCV) infection in liver transplant (LT) recipients. The aim of the study was to assess immunosuppression needs after achieving a sustained viral response (SVR). Methods: We compared immunosuppression needs before and after achieving a SVR in adult LT recipients treated for recurrent HCV infection with all-oral direct acting agents. Results: We identified 52 liver LT treated recipients who achieved a SVR. The median (25th and 75th percentile interquartile range [IQR]) age was 62 years (57.75, 65). Most recipients received tacrolimus (TAC) for their immunosuppressant regimen. After achieving SVR, there was no statistically significant difference in daily dose of TAC unadjusted per weight (p > 0.05). However, there was a statistically significant decrease in daily dose of TAC adjusted per weight, serum levels of TAC, and the product of glomerular filtration rate and TAC. No statistically significant differences in cyclosporine unadjusted/adjusted per weight daily dose or serum levels were noted. Conclusions: Immunosuppression needs were increased for those patients treated with TAC but not cyclosporine. LT recipients prescribed TAC require close monitoring after treatment completion to avoid potential risk of acute rejection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|